Changeflow GovPing Pharma & Drug Safety EPO Patent EP4499128A1: Ligand Potentiation Met...
Routine Notice Added Final

EPO Patent EP4499128A1: Ligand Potentiation Methods

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Pharma (A61K)
Published March 18th, 2026
Detected March 24th, 2026
Email

Summary

The European Patent Office published patent application EP4499128A1 on March 18, 2026, detailing methods and compositions for ligand potentiation. The patent lists Mark W. Grinstaff, Jack R. Kirsch, and Amanda K. Williamson as applicants and inventors.

What changed

This document is a publication of a European patent application (EP4499128A1) related to methods and compositions for potentiating a ligand. The patent application was published on March 18, 2026, and lists Mark W. Grinstaff, Jack R. Kirsch, and Amanda K. Williamson as the inventors and applicants. The International Patent Classification (IPC) codes indicate relevance to pharmaceutical preparations and therapeutic uses.

As this is a patent publication, it does not impose direct compliance obligations or deadlines on regulated entities. However, it may be of interest to pharmaceutical companies and drug manufacturers involved in research and development, as it pertains to novel methods and compositions in the field of ligand potentiation. Legal and R&D departments should review this publication for potential intellectual property considerations and competitive intelligence.

Source document (simplified)

← EPO Patent Bulletin

METHODS AND COMPOSITIONS FOR POTENTIATION OF A LIGAND

Publication EP4499128A1 Kind: A1 Mar 18, 2026

Applicants

Grinstaff, Mark W., Kirsch, Jack R., Williamson, Amanda K.

Inventors

Grinstaff, Mark W., Kirsch, Jack R., Williamson, Amanda K.

IPC Classifications

A61K 38/22 20060101AFI20260210BHEP A61K 31/573 20060101ALI20260210BHEP A61P 7/04 20060101ALI20260210BHEP A61K 45/06 20060101ALI20260210BHEP A61K 9/00 20060101ALI20260210BHEP A61K 31/167 20060101ALI20260210BHEP A61K 9/16 20060101ALI20260210BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

METHODS AND COMPOSITIONS FOR POTENTIATION OF A LIGAND

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4499128A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Intellectual Property Management
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property Medical Research

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.